- Home
- AMPL vs AUPH Comparison
AMPL vs AUPH Comparison
Compare AMPL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMPL | AUPH |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMPL | AUPH |
|---|---|---|
| Price | $7.51 | $14.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | $13.50 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 2.9M | 784.5K |
| Earning Date | 05-20-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.84 | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $343,214,000.00 | $283,055,000.00 |
| Revenue This Year | $15.94 | $17.79 |
| Revenue Next Year | $14.98 | $15.50 |
| P/E Ratio | ★ N/A | $6.80 |
| Revenue Growth | 14.68 | ★ 20.38 |
| 52 Week Low | $6.00 | $6.83 |
| 52 Week High | $14.27 | $16.54 |
Technical Indicators
Market Signals| Indicator | AMPL | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 41.76 |
| Support Level | $6.00 | $11.05 |
| Resistance Level | $7.74 | $16.28 |
| Average True Range (ATR) | 0.58 | 0.48 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 87.93 | 43.49 |
Price Performance
Historical ComparisonAbout AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.